Details of the Drug Combination

General Information of Drug Combination (ID: DCBFZHO)

• Drug Combination Name: Vinflunine + Hepzato
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  Vinflunine (DMTJAEP): Small molecular drug
  Hepzato (DM2AZPP): N.A.
• High-throughput Screening Result:
  Testing Cell Line: HCT-15
  Zero Interaction Potency (ZIP) Score: 3.48
  Bliss Independence Score: 5.89
  Loewe Additivity Score: 1.02
  LHighest Single Agent (HSA) Score: 0.13

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DCASY1N	HL-60(TB)	Investigative	[4]
Carcinoma	DCFLQAD	MCF7	Investigative	[5]
Adenocarcinoma	DCLOPGX	HT29	Investigative	[1]
High grade ovarian serous adenocarcinoma	DC9X6C6	OVCAR-5	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.